Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Swiss independent drug development company Debiopharm has conducted a study in patients with HIV that demonstrates the tolerability and efficacy of its investigational drug Debio-025.
Subscribe to our email newsletter
The aim of the study was to assess the safety of repeated oral doses of Debio-025, to determine its pharmacokinetic profile and antiviral effect in the patients. The results confirm the tolerability and safety of Debio-025 in the infected subjects.
Debio-025 is a synthetic first-in-class non-immunosuppressive cyclosporin, being tested in humans as a potential anti-HIV-1 drug. Debio-025 binds strongly to cyclophilins, host cell proteins thought to confer a replication advantage to HIV-1. Its potent inhibitory activity on the HIV replication was shown in preclinical studies.
The results of the 10 day treatment with once daily oral doses show that Debio-025 was well tolerated at all dose levels (50, 400 and 1200mg). It was also rapidly absorbed after administration. In 11 out of 36 subjects treated with Debio-025, anti-HIV-1 activity was observed: nine showed a viral load reduction lower or equal to 0.5 log10 and two a reduction higher to 1.0 log10.
“The results of this study are promising. Debio-025 was well tolerated by the infected subjects. We are conducting a clinical study to establish the potential of Debio-025 as an anti-viral compound,” said Rolland-Yves Mauvernay, president and CEO of Debiopharm.